BIIB News and Press, Biogen Inc. From 11/13/23

2023-11-13 05:41:04 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) on Saturday shared positive clinical findings from an ongoing trial of its investigational antisense medicine, ION582, in Angelman syndrome (AS). ION582, which is being developed under a strategic collaboration wi...

2023-11-10 16:05:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-10 06:50:00 ET It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth market. And with more medicines slated to hit the market relatively soon, ...

2023-11-08 16:03:41 ET Summary Biogen faces MS market challenges, shifts focus to rare diseases/Alzheimer’s drugs like Skyclarys and Leqembi, balancing clinical innovation and financial health. Q3 reports slight revenue dip, increased R&D, and SG&A expenses, ending ...

2023-11-08 14:15:20 ET Image source: The Motley Fool. Biogen (NASDAQ: BIIB) Q3 2023 Earnings Call Nov 08, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Biogen (BIIB) Q3 2023 Earnings Call Transcript

2023-11-08 13:03:03 ET Biogen Inc. (BIIB) Q3 2023 Results Earnings Conference Call November 8, 2023, 08:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of ...

2023-11-08 07:40:46 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...

2023-11-08 07:03:36 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Biogen Inc. (BIIB) is expected to report $3.97 for Q3 2023